In the current study, we aim to understand the role of CD13 in MDR and evaluate the antitumor effect of BC-02, a novel mutual prodrug (hybrid drug) of bestatin and 5FU, which can be degraded into bestatin and 5FU (Dou et al., 2017), on drug-resistant tumor cells. Here, ANPEP is linked to neoplasm.